Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor

Sarka Nemeckova 1,*, Kamila Alexova-Zurkova 1, Petr Hainz 1, Jitka Krystofova 1, Jana Mackova 1, Katerina Roubalova 1, Marketa Stastna-Markova 1,2, Milena Vrana 1 and Jan Vydra 1,2

1 Institute of Haematology and Blood Transfusion, CZ-128 20 Prague, Czech Republic; kamila.zurkova@uhkt.cz (K.A.-Z.); petr.hainz@uhkt.cz (P.H.); jitra.krystofova@uhkt.cz (J.K.); jana.mackova@uhkt.cz (J.M.); katerina.roubalova@uhkt.cz (K.R.); marketa.markova@uhkt.cz (M.S.-M.); milena.vrana@uhkt.cz (M.V.); jan.vydra@uhkt.cz (J.V.)

2 Institute of Clinical and Experimental Hematology, 1st Faculty of Medicine, Charles University, CZ-121 08 Prague, Czech Republic

* Correspondence: sarka.nemeckova@uhkt.cz; Tel.: +420-221-977-269

Simple Summary: Our study describes an AML patient whose leukemia cells carried the NPM1c+ mutation, and who was the recipient of allogeneic HSCT from a haploidentical donor. The patient raised a robust allorestricted CD8+ T cell response directed against the NPM1wt protein. Favourably, the response against NPM1wt was not accompanied by side effects such as GvHD. Moreover, the induction of a high NPM1wt-specific response coincided with the decrease in NPM1c+ transcripts detected, implying a beneficial graft versus leukemia effect. On the basis of these results, we suppose that TCRs from allorestricted NPM1wt-specific T cells are worth studying in other recipients of grafts from haploidentical donors as a possible tool for TCR gene therapy.

Abstract: Nucleophosmin (NPM1, B23) is a multifunctional phosphoprotein expressed in all tissues. The protein is mainly localized in nucleoli and rapidly travels between the nucleus and the cytoplasm. NPM1 is involved in multiple cellular functions (for review see Falini B et al. [1]), such as ribosome assembly and export, centrosome duplication and cell cycle control, DNA repair, histone- and protein-chaperone activity, 2-O-methylation of rRNA, and response to stress stimuli. NPM1 is overexpressed in many types of solid human cancers. In some cases, meta-analyses have indicated that NPM1-increased

Keywords: acute myeloid leukemia; T cell response; nucleophosmin 1; mutation; hematopoietic stem cell transplantation

1. Introduction

Nucleophosmin (NPM1, B23) is a multifunctional phosphoprotein (37 kDa), expressed ubiquitously in all tissues. The protein is mainly localized in nucleoli and rapidly travels between the nucleus and the cytoplasm. NPM1 is involved in multiple cellular functions (for review see Falini B et al. [1]), such as ribosome assembly and export, centrosome duplication and cell cycle control, DNA repair, histone- and protein-chaperone activity, 2-O-methylation of rRNA, and response to stress stimuli. NPM1 is overexpressed in many types of solid human cancers. In some cases, meta-analyses have indicated that NPM1-increased
expression correlates with the mitotic index and with the stage of tumor progression, and may act as a valuable prognosis biomarker and a potential therapeutic target in human solid tumors [2,3].

In hematological malignancies, NPM1 belongs to commonly altered genes. Its mutation is always heterozygous and causes a dominant negative phenotype. In 30% of patients with acute myeloid leukemia (AML), NPM1 mutations typically consist of 4-base pair frameshift duplication or insertion within exon 12 of the gene [4,5]. The frameshift results in the substitution of 7 C-terminal amino acids for a new 11 amino acid sequence. This leads to the loss of the nucleolar localization signal (NoLS) and the generation of a novel nuclear export signal (NES), which re-localizes the NPM1 mutant protein from the nucleolus to the cytoplasm (NPM1 cytoplasmic or NPM1c+). The oligomerization of NPM1c+ with non-mutated nucleophosmin (NPM1wt) results in the delocalization of the majority of the latter and in a reduction in NPM1wt content in the nucleoli [1].

The sequence of 11 residues of the C-terminus of all types of mutated NPM1 proteins code for several unique oligopeptides that have been shown to function as leukemia-specific neoantigens. Several peptide epitopes derived from the C-terminal-mutated sequence were predicted in silico, and their function as ligands of specific T cells have been confirmed in vitro and in vivo. For a complete list of epitopes, see Table 1 in the review of Forghieri et al. [6]. It was shown that the frequency of specific T-cell responses against the mutated C-terminus differed significantly between AML patients with NPM1c+ and healthy volunteers [7].

Previous studies have shown that the NPM1wt protein is also immunogenic. Chronic graft versus host reaction in patients after bone marrow transplantation elicited antibodies specific for the NPM1wt [8]. Cytotoxic T-lymphocyte (CTL) lines recognizing the NPM1wt protein sequences which were able to lyse tumor cells overexpressing NPM1wt were derived from patients with colorectal cancer [9]. It has been shown in several studies of HLA ligandome [10–12] that peptides from cleaved NPM1wt are frequently found in complex with HLA in healthy blood cells and tumor cells, thus contributing to its role as a target for specific T cells. Whereas the NPM1c+ neoantigen may be considered an ideal targetable antigen for AML immunotherapy, the NPM1wt, under normal conditions, induces tolerance to the autoantigen by deletion of specific T cell clones. However, in the presence of detrimental allo-HLA immune responses after the transplantation of HLA-mismatched stem cells, T cells with high avidity for other autoantigens can be isolated from patients, as has been shown for the PRAME antigen [13]. Similarly, high-avidity T cells were induced by ex vivo stimulation with tumor antigens on HLA-mismatched antigen-presenting cells [14–16].

The aim of our study was to analyze the T cell response specific for both mutated NPM1c+ and NPM1wt elicited in a hematopoietic stem cell transplant (HSCT) recipient with AML harboring NPM1c+ mutation.

2. Material and Methods

2.1. Patient and Donor

A 64-year-old man (ID 1515) with acute myeloid leukemia with NPM1 mutation underwent HSCT from a haploidentical related donor, as a treatment of a molecular relapse of AML after his first complete remission. Genetic analysis at the time of diagnosis revealed normal karyotype, positivity for NPM1-type A, and DNMT3A mutations. At the time of transplantation, bone marrow examination showed morphologic CR with minimal residual disease detected with flow cytometry (LAIP 0.04, LSC below the detection limit), and RT-PCR (NPM1c+ level was 2 copies/10^4 abl mRNA). The patient’s HLA typing was: HLA-A*11:01; *23:01, HLA-B*13:02; *35:01, HLA-C *04:01; *06:02, DRB1 *01:01; *07:01, DQB1*05:01; *02:02, DPB1*04:01; *17:01. His 39-year-old son, who was HLA-genotypically haploidentical to the patient (HLA-A*23:01; *32:01, HLA-B*13:02; *15:01, HLA-C*03:03; *06:02, DRB1 *07:01; *08:03, DQB1 *02:02, *03:01, DPB1 *04:02; *17:01), was selected to serve as the HSC donor. The monitoring of NPM1c+ transcripts
revealed a molecular relapse in bone marrow two months after HSCT (increase in the amount of NPM1c+ transcripts from 2 to 22 copies/10^4 abl, Figure 1A). The signal of NPM1c+ was never found in the peripheral blood. The patient received pre-emptive donor lymphocyte infusions (DLI) (3 × 10^5/kg and 1 × 10^6/kg) on day 135 and 166, respectively, which resulted in a drop in NPM1c+ positivity. The absence of NPM1c+ transcripts in bone marrow lasted for a subsequent 17 months. The patient developed no severe complications, no GvHD or microbial infections. The patient was enrolled in an institutional clinical study to monitor the reconstitution of the immune system after transplantation. The patient signed an informed consent form. The study was approved by the institutional ethical board.

Figure 1. Nucleophosmin-specific T cell responses in an AML patient after HSCT. (A) Frequency of spot-forming units (SFU) specific for NPM1wt detected by ELISPOT-IFNγ and result of quantification of NPM1c+ transcripts in bone marrow. Time of DLI is denoted by arrows. (B) The phenotype of NPM1wt-specific T cells at month +3 producing IFNγ determined by IC FACS. (C) Frequency of T cells specific for CTL epitopes 93-EITPPVVLK, 142-RSAPGGGSK, 194-KSIRDTPAKNAQK, 242-SSVEDIKAK, and 259-GSLPKVEAK determined at month +5. Statistical analysis was performed using the Mann–Whitney test (A, C) **** p < 0.0001, *** p < 0.001, * p < 0.05.

2.2. Detection of LAA-Specific T Cells

The isolation of PBMCs from patient blood and the measurement of LAA-specific T cell responses by ELISPOT-IFNγ and IC-FACS have been described in detail recently [17]. In brief, the patient’s PBMCs were pulsed with peptide pools and cultured in vitro in the presence of IL4 and IL7 for 11 days. Thereafter, the antigen-specific recall (PepMix 1 μg/mL) response of T cells was detected by ELISPOT-IFNγ or by IC-FACS. Pools of 15 amino acid long overlapping peptides (PepMixTM) covering the full-length sequence of
WT1, PRAME, MUC1, CCNA1, NPM1wt protein, and the C-terminal region of the NPM1c type A were purchased from JPT Peptide Technologies GmbH (Berlin, Germany). Five candidate NPM1wt CTL epitopes, 93-EITPPVVLR, 142-RSAPGGGSK, 194-KSIRDTPAKNAQK, 242-SSVEDIKAK, and 259-GSLPKVEAK, restricted by HLA-A*11:01, were predicted using the Sylpeithi [18] and NetCTLpan [19] algorithms and synthesized by JPT Peptide Technologies GmbH.

3. Results

The patient (ID 1515) took part in an institutional clinical study monitoring the reconstitution of the T cell response against LAA, including WT1, PRAME, NPM1wt, NPM1c+, MUC1, and CCNA1. The response was measured at post-HSCT months 1, 2, 3, 4, 5, 7, and 11 by ELISPOT-IFNγ (Figure 1A, Figure 2). Antigen-specific T cell response against any LAA was entirely negative at post-HSCT month +1. Then, the T cell response against NPM1wt (Figure 1A) rose enormously to 880 spots per 2.5 × 10^5 cells at month +2 and remained significantly positive at months +4 and +5. Subsequently, it gradually declined and there was no significant difference in the response between NPM1wt-stimulated and unstimulated T cells at month +7. Later on, a high number of 800 spots appeared again at month +11. Concerningly, T cells against other LAA (Figure 2) with spots specific for PRAME and MUC1 were found at months +7 and +11. It should be noted that the decline in NPM1c+ transcript level had already started before administration of the first DLI; hence, it was associated with the presence of NPM1wt-specific T cells. The detection of intracellular IFNγ by IC-FACS (Figure 1B) revealed that the NPM1wt-responding T cell population at month +3 consisted mainly of CD8+ T cells, 80% of which were of the memory CD45RO+ phenotype. Our next goal was to identify epitopes recognized by the patient’s T cells. PBMCs collected at month +5 were pulsed with NPM1wt PepMix, expanded for 11 days in vitro, and thereafter restimulated with NPM1wt peptide MHC I epitopes. Measurement of the response by ELISPOT-IFNγ (Figure 1C) showed that the 93-EITPPVVLR epitope was recognized by T cells. The response elicited by other peptides was lower and insignificant in comparison with unstimulated cells.

Figure 2. Monitoring of LAA-specific T cell responses in an AML patient after HSCT. Frequency of SFU specific for Wilm’s tumor antigen (WT-1), PRAME, mutated NPM1c+, mucin (MUC-1) and cyclin A1 (CCNA1) was detected by ELISPOT-IFNγ. Statistical analysis was performed using the Mann–Whitney test ** p < 0.01, * p < 0.05.
4. Discussion

In this study, we monitored the response of T cells against LAA in a transplanted AML patient whose leukemia cells carried the \( NPM1c^+ \) (type A) mutation. A mighty response of \( CD8^+ \) T cells directed against the \( NPM1^{wt} \) protein was found between months +2–+5 and at +11 month after transplantation, and coincided with an early molecular relapse detected as an increase in \( NPM1c^+ \) transcripts in bone marrow between months +2 and +6. When compared with other LAA, the T cell response of the presented patient against \( NPM1^{wt} \) was much higher and differed significantly by frequency, phenotype, and dynamics. Unlike T cells against other LAA, which were mostly \( CD4^+ \) (not shown), \( NPM1^{wt} \)-specific T cells in this case were of the \( CD8^+ \) phenotype. The peak of anti-\( NPM1^{wt} \) response (880 spot forming units (SFU)) was detectable as early as month +2 after transplantation, which may imply that the response was mediated by alloresticted memory T cells of donor origin. This presumption was confirmed by finding a positive IFN\( \gamma \) response after restimulation with minimal epitope 93- EITPPVVLR, which was predicted to be efficiently recognized in the context of the mismatched HLA-A*11:01 molecule of the recipient. The high frequency of \( NPM1^{wt} \)-specific T cells may suggest that they were memory T cells generated by the donor in response to a heterologous antigen and that, after transplantation, they cross-reacted with \( NPM1^{wt} \) peptides derived from AML blasts in the context of the allo-HLA-A*11:01 molecule. The T cells which recognize \( NPM1^{wt} \)-derived peptides in the context of their own HLA should be clonally deleted in healthy subjects. However, due to molecular mimicry, T cells of other specificity may recognize them under allogeneic conditions. The mechanism resembles the phenomenon called heterologous immunity [20], as observed in virus-infected kidney transplant recipients. It was shown [21,22] that, in those patients, HCMV-specific CD8(+) T cells can cross-react with alloantigens presented by mismatched or matched HLA molecules. Such cross-reactive T cells may damage the transplanted organ by a strong immune reaction. Notably, these cross-reactive T cells were detectable in the first few weeks following transplantation, but could not be detected in later months [21], thus resembling the kinetics of \( NPM1^{wt} \)-specific T cells seen in our patient. A similar immune response was reported by Amir et al. [13] in association with hematopoietic stem cell transplantation. The authors isolated a clone of high-avidity allo-HLA-restricted T cells specific for tumor associated antigen PRAME from an AML patient with GvHD after the transplantation of stem cells from a mismatched donor. Moreover, some authors speculate that upregulation and subcellular delocalization of the complex in AML blasts containing the mutated \( NPM1c^+ \) molecule could enhance immunogenicity of the common \( NPM1^{wt} \) sequence [23]. Another explanation of our results could be the \( NPM1c^+ \)-associated modulation of antigen processing machinery such as proteasome [24], immunoproteasome, or autophagy [25] involved in protein cleavage and peptide transport, and/or MHC I complex formation, and/or the modification of these antigen-presenting functions resulting from the different sensitivities of \( NPM1c^+ \) cells to proinflammatory cytokines [26]. All these hypotheses have yet to be experimentally tested.

Surprisingly, we did not detect T cell response against \( NPM1c^+ \)-derived neoepitopes in our patient. Either these epitopes could not be presented in the context of the donor HLA, or the priming of such a response under highly immunosuppressive conditions during the first months after HSCT was ineffective. Minimal epitopes used in our study were predicted in silico as binders of HLA-A*11:01. Two of them, 93- EITPPVVLR and 194-KSIRDTPAKNAQk, were also detected as the true ligands of HLA-A*11 molecules on AML blasts [12], various other malignant cells, and the leukocytes of healthy subjects [10,11].

5. Conclusions

Our study has shown, for the first time, that an AML patient can mount a mighty T cell response against an autoantigen, the \( NPM1^{wt} \), under conditions of allogeneic HSCT from a haploidentical donor. Favorably, the allorestricted response against \( NPM1^{wt} \) persisting for 11 months was not accompanied by side effects such as GvHD during this period. Moreover, the induction of a high \( NPM1^{wt} \)-specific response coincided with the decrease
in NPM1c+ transcripts detected, implying a beneficial graft versus leukemia effect. On the basis of these results, we suppose that TCRs from allorestricted NPM1wt-specific T cells are worth studying in other recipients of graft from a haploidentical donor as a possible tool for TCR gene therapy.

**Author Contributions:** S.N. was responsible for designing the study protocol, analyzing data, interpreting results and writing the report; K.A.-Z. conducted flow cytometry measurement and analyses of data; P.H. and J.K. conducted measurement of T cell responses by ELISPOT and IC-FACS; J.M. performed processing of blood samples and testing of T cell responses; K.R. was responsible for designing the study protocols, management of blood sampling and writing the original draft; M.S.-M. and J.V. were responsible for the recruitment of patients in the study, the interpretation of data, and writing the report; M.V. was responsible for HLA typing. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was financially supported by the European regional development fund (ERDF) project AIIHHP CZ.02.1.01/0.0/0.0/16_025/0007428, OP RDE and the Project for conceptual development of the research organization No 00023736.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or ethics committee) of Institute of Hematology and Blood Transfusion (protocol code EK 7/AVZ/01/2021) on 15 January 2021.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** All data relating to this study are reported in the manuscript and figures.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Falini, B.; Brunetti, L.; Sportoletti, P.; Martelli, M.P. NPM1-mutated acute myeloid leukemia: From bench to bedside. *Blood* 2020, 136, 1707–1721. [CrossRef]

2. Chen, S.; He, H.; Wang, Y.; Liu, L.; Liu, Y.; You, H.; Dong, Y.; Lyu, J. Poor prognosis of nucleophosmin overexpression in solid tumors: A meta-analysis. *BMC Cancer* 2018, 18, 1–8. [CrossRef]

3. Grisendi, S.; Mecucci, C.; Falini, B.; Pandolfi, P.P. Nucleophosmin and cancer. *Nat. Cancer* 2006, 6, 493–505. [CrossRef]

4. Falini, B.; Mecucci, C.; Tacci, E.; Alcalay, M.; Rosati, R.; Pasqualucci, L.; La Starza, R.; Diverio, D.; Colombo, E.; Santucci, A.; et al. Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype. *N. Engl. J. Med.* 2005, 352, 254–266. [CrossRef]

5. Papaemmanuil, E.; Gerstung, M.; Bullinger, L.; Gaidzik, V.I.; Paschka, P.; Roberts, N.D.; Potter, N.E.; Heuser, M.; Thol, F.; Bolli, N.; et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. *N. Engl. J. Med.* 2016, 374, 2209–2221. [CrossRef]

6. Forghieri, F.; Riva, G.; Lagreca, I.; Barozzi, P.; Vallerini, D.; Morselli, M.; Paolini, A.; Bresciani, P.; Colaci, E.; Maccaferri, M.; et al. Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. *Oncotarget* 2019, 10, 869–882. [CrossRef]

7. Greiner, J.; Ono, Y.; Hofmann, S.; Schmitt, A.; Mehring, E.; Götz, M.; Guillaume, P.; Döhner, K.; Mytilineos, J.; Döhner, H.; et al. Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia. *Blood* 2012, 120, 1282–1289. [CrossRef]

8. Wesierska-Gadek, J.; Penner, E.; Hitchman, E.; Kier, P.; Sauermann, G. Nucleolar proteins B23 and C23 as target antigens in chronic graft-versus-host disease. *Blood* 1992, 79, 1081–1086. [CrossRef]

9. Swoboda, R.K.; Somasundaram, R.; Caputo, L.; Berencsi, K.; Von Franzke, P.; Taylor, D.D.; Marincola, F.M.; Meropol, N.J.; Sigurdson, E.; Miller, E.; et al. Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient. *Int. J. Cancer* 2009, 127, 1124–1130. [CrossRef]

10. Pearson, H.; Daouda, T.; Granados, D.P.; Durette, C.; Bonneil, E.; Courcelles, M.; Rodenbrock, A.; Laverdure, J.-P.; Côté, C.; Mader, S.; et al. MHC class I–associated peptides derive from selective regions of the human genome. *J. Clin. Investig.* 2016, 126, 4690–4701. [CrossRef]

11. Shraibman, B.; Barnea, E.; Kadosh, D.M.; Haimovich, Y.; Slobodin, G.; Rosner, I.; López-Larrea, C.; Hilf, N.; Kuttruff, S.; Song, C.; et al. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. *Mol. Cell. Proteom.* 2019, 18, 1255–1268. [CrossRef]
12. Narayan, R.; Olsson, N.; Wagar, L.E.; Medeiros, B.C.; Meyer, E.; Czerwinski, D.; Khodadoust, M.S.; Zhang, L.; Schultz, L.; Davis, M.M.; et al. Acute myeloid leukemia immunoepitodome reveals HLA presentation of mutated nucleophosmin. PLoS ONE 2019, 14, e0219547. [CrossRef]

13. Amir, A.L.; Van Der Steen, D.M.; Van Loenen, M.M.; Hagedoorn, R.S.; De Boer, R.; Kester, M.D.; De Ru, A.H.; Lugthart, G.; van Kooten, C.; Hiemstra, P.; et al. PRAME-Specific Allo-HLA–Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer. Clin. Cancer Res. 2011, 17, 5615–5625. [CrossRef]

14. Wilde, S.; Sommermeyer, D.; Frankenberg, B.; Schemann, M.; Milosevic, S.; Spranger, S.; Pohla, H.; Uckert, W.; Busch, D.H.; Schendel, D.J. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood 2009, 114, 2131–2139. [CrossRef]

15. Münz, C.; Obst, R.; Osen, W.; Stevanović, S.; Rammensee, H.G. Alloreactivity as a source of high avidity peptide-specific human CTL. J. Immunol. 1999, 162, 25–34.

16. Sadovnikova, E.; Stauss, H.J. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: Reagents for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 1996, 93, 13114–13118. [CrossRef]

17. Štastná-Marková, M.; Hamšíková, E.; Hainz, P.; Hubáček, P.; Kroutílová, M.; Kryštofova, J.; Ludviková, V.; Musil, J.; Pecherková, P.; Saláková, M.; et al. Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT. Vaccines 2021, 9, 1226. [CrossRef]

18. Rammensee, H.-G.; Bachmann, J.; Emmerich, N.P.N.; Bachor, O.A.; Stevanović, S. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 1999, 50, 213–219. [CrossRef]

19. Stranzl, T.; Larsen, M.V.; Lundegaard, C.; Nielsen, M. NetCTLpan: Pan-specific MHC class I pathway epitope predictions. Immunogenetics 2010, 62, 357–368. [CrossRef]

20. Ford, M.L. Virally-induced heterologous immunity in renal transplant recipients: Important or inconsequential? Am. J. Transplant. 2016, 16, 1348–1349. [CrossRef]

21. Heutinck, K.M.; La Yong, S.; Tonneijck, L.; Heuvel, H.V.D.; Van Der Weerd, N.C.; Van Der Pant, K.A.; Bemelman, F.J.; Claas, F.H.; Berge, I.J.T. Virus-Specific CD8+ T Cells Cross-React to Donor-Alloantigen Are Transiently Present in the Circulation of Kidney Transplant Recipients Infected with CMV and/or EBV. Am. J. Transplant. 2016, 16, 1480–1491. [CrossRef] [PubMed]

22. Stranavova, L.; Pelak, O.; Svaton, M.; Hrubá, P.; Fronkova, E.; Slavcev, A.; Osečková, K.; Malusková, J.; Hubáček, P.; Froněk, J.; et al. Heterologous Cytomegalovirus and Allo-Reactivity by Shared T Cell Receptor Repertoire in Kidney Transplantation. Front. Immunol. 2019, 10, 2549. [CrossRef] [PubMed]

23. Kuzelová, K.; Brodská, B.; Fuchs, O.; Dobrovolná, M.; Soukup, P.; Četkovský, P. Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Nucleophosmin Immune Response in Acute Myeloid Leukemia. PLoS ONE 2015, 10, e0127637. [CrossRef] [PubMed]

24. Martelli, M.P.; Gionfriddo, I.; Mezzasoma, F.; Milano, E.; Pierangeli, S.; Mulas, F.; Pacini, R.; Tabarrini, A.; Pettirossi, V.; Rossi, R.; et al. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood 2015, 125, 3455–3465. [CrossRef] [PubMed]

25. Du, W.; Xu, A.; Huang, Y.; Cao, J.; Zhu, H.; Yang, B.; Shao, X.; He, Q.; Ying, M. The role of autophagy in targeted therapy for acute myeloid leukemia. Autophagy 2020, 17, 2665–2679. [CrossRef]

26. Carey, A.; Edwards, D.K.; Eide, C.A.; Newell, L.; Traer, E.; Medeiros, B.C.; Pollyea, D.A.; Deininger, M.W.; Collins, R.H.; Tyner, J.W.; et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 2017, 18, 3204–3218. [CrossRef]